AD2C Program

About Acepodia

Acepodia is developing first-in-class, allogeneic cell therapies using its proprietary Antibody-Cell Conjugation (ACC) and Antibody-Dual-Drugs Conjugation (AD2C) platforms. Founded in 2017 with deep roots in Nobel laureate Carolyn Bertozzi's lab, the company has advanced multiple programs into Phase 1 clinical trials for oncology and autoimmune indications and secured strategic partnerships with industry leaders like Pfizer. Its strategy leverages a unique chemical conjugation approach to create readily available 'immune cell engagers' targeting both hematologic malignancies and solid tumors, aiming to democratize cell therapy access.

Therapeutic Areas